论文部分内容阅读
近10年在急性髓细胞白血病(AML)治疗方面取得了某些进展,但老年患者仍预后较差。其原因可能有两个:老年人对白血病及强烈化疗的耐受性差而使治疗相关死亡增加;老年白血病在生物学和临床上均不同于年轻病人,其肿瘤细胞对细胞毒药物敏感性较低。作者通过多中心临床Ⅱ期试验观察了V-TAD方案治疗35例老年白血病的疗效和毒副作用。
Some progress has been made in the treatment of acute myeloid leukemia (AML) in recent 10 years, but elderly patients still have a poor prognosis. There are two possible reasons for this: older people are more tolerant of leukemia and aggressive chemotherapy, resulting in increased treatment-related deaths; older patients are younger and younger, both biologically and clinically, and their tumor cells are less susceptible to cytotoxic drugs . The authors observed the efficacy and side effects of V-TAD regimen in the treatment of 35 cases of senile leukemia by multi-center phase II clinical trial.